Legal status · United States
Is Visepegenatide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Visepegenatide is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Visepegenatide in the United States at a glance
| Classification | Not approved; research use only |
|---|---|
| Note | No FDA approval. A phase 2 study was conducted in the United States; the phase 3 was run entirely in China. |
| FDA approval status | Not approved in the United States. Reported approved in China in November 2025 after the published phase 3; this site has not resolved a Chinese regulatory document, so treat the approval date as reported rather than as verified here. |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Visepegenatide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Visepegenatide is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Visepegenatide is
A published phase 3 in 273 treatment-naive Chinese adults cut glycated haemoglobin 1.36 percentage points against 0.63 on placebo at 24 weeks, and it needs no dose titration. In its phase 1 study 28 percent of healthy volunteers developed antidrug antibodies.
Visepegenatide is exenatide with a polyethylene glycol chain attached, which turns a twice-daily injection into a once-weekly one. It comes from PegBio in Hangzhou and carried the development code PB-119 through most of its published literature.
Mechanism: Exenatide, a synthetic version of exendin-4 from Gila monster venom that acts as a GLP-1 receptor agonist, covalently modified with polyethylene glycol. The PEG chain increases hydrodynamic radius and slows renal clearance, extending half-life from the few hours of native exenatide to around 55 hours, which supports weekly dosing at a fixed dose.
Regulatory history: Not approved in the United States. Reported approved in China in November 2025 after the published phase 3; this site has not resolved a Chinese regulatory document, so treat the approval date as reported rather than as verified here.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Visepegenatide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Visepegenatide in other countries
Frequently asked questions
Is Visepegenatide legal in the United States?
No. Visepegenatide is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: No FDA approval. A phase 2 study was conducted in the United States; the phase 3 was run entirely in China.
Can I buy Visepegenatide in the United States?
No approved product exists to buy. In the United States Visepegenatide is classified as "Not approved; research use only", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: No FDA approval. A phase 2 study was conducted in the United States; the phase 3 was run entirely in China.
Is Visepegenatide FDA approved?
No. FDA status: Not approved in the United States. Reported approved in China in November 2025 after the published phase 3; this site has not resolved a Chinese regulatory document, so treat the approval date as reported rather than as verified here.. Current US classification: "Not approved; research use only". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Visepegenatide live on its compound profile.
Visepegenatide profileThis page is general information about the regulatory status of Visepegenatide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.